Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 9
2021 23
2022 22
2023 20
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition.
Cárdenas-Rodríguez N, Ignacio-Mejía I, Correa-Basurto J, Carrasco-Vargas H, Vargas-Hernández MA, Albores-Méndez EM, Mayen-Quinto RD, De La Paz-Valente R, Bandala C. Cárdenas-Rodríguez N, et al. Int J Mol Sci. 2024 Mar 29;25(7):3805. doi: 10.3390/ijms25073805. Int J Mol Sci. 2024. PMID: 38612615 Free PMC article. Review.
The post-COVID condition (PCC) is a pathology stemming from COVID-19, and studying its pathophysiology, diagnosis, and treatment is crucial. ...This review involved an exhaustive search in specialized databases including PubMed, PubChem, ProQuest, EBSCO, Scop …
The post-COVID condition (PCC) is a pathology stemming from COVID-19, and studying its pathophysiology, diagnosis, and …
Safety and risks of CBD oils purchased online: unveiling uncertain quality and vague health claims.
Vida RG, Strauss LV, Bajtel Á, Kiss T, Csupor D, Fittler A. Vida RG, et al. Front Pharmacol. 2023 Dec 14;14:1273540. doi: 10.3389/fphar.2023.1273540. eCollection 2023. Front Pharmacol. 2023. PMID: 38192407 Free PMC article.
Introduction: The unmet need for highly effective, naturally derived products with minimal side effects results in the over-popularity of ever-newer medicinal plants. In the middle of 2010, products containing cannabidiol (CBD), one of the special metabolites of Can …
Introduction: The unmet need for highly effective, naturally derived products with minimal side effects results in the over-popularity of ev …
Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial.
Thurgur H, Lynskey M, Schlag AK, Croser C, Nutt DJ, Iveson E. Thurgur H, et al. Br J Clin Pharmacol. 2024 Apr;90(4):1081-1093. doi: 10.1111/bcp.15988. Epub 2024 Jan 17. Br J Clin Pharmacol. 2024. PMID: 38105651
AIMS: To conduct a single-arm open-label feasibility trial of the safety and tolerability of a full-spectrum cannabidiol (CBD)-dominant cannabis-based medicinal product for treating the symptoms of long COVID. ...CONCLUSION: The study drug was safe and well-t …
AIMS: To conduct a single-arm open-label feasibility trial of the safety and tolerability of a full-spectrum cannabidiol (CBD) …
Cannabidiol - Help and hype in targeting mucosal diseases.
Moniruzzaman M, Janjua TI, Martin JH, Begun J, Popat A. Moniruzzaman M, et al. J Control Release. 2024 Jan;365:530-543. doi: 10.1016/j.jconrel.2023.11.010. Epub 2023 Dec 5. J Control Release. 2024. PMID: 37952828 Free article. Review.
Cannabidiol (CBD) is one of the most commonly utilised phytocannabinoids due to its non-psychoactive and multiple potential therapeutic properties and its non-selective pharmacology. ...Although CBD products are generally treated as a restricted substance, th …
Cannabidiol (CBD) is one of the most commonly utilised phytocannabinoids due to its non-psychoactive and multiple potential th …
Mannich-type modifications of (-)-cannabidiol and (-)-cannabigerol leading to new, bioactive derivatives.
Lőrincz EB, Tóth G, Spolárics J, Herczeg M, Hodek J, Zupkó I, Minorics R, Ádám D, Oláh A, Zouboulis CC, Weber J, Nagy L, Ostorházi E, Bácskay I, Borbás A, Herczegh P, Bereczki I. Lőrincz EB, et al. Sci Rep. 2023 Nov 10;13(1):19618. doi: 10.1038/s41598-023-45565-7. Sci Rep. 2023. PMID: 37949940 Free PMC article.
(-)-Cannabidiol (CBD) and (-)-cannabigerol (CBG) are two major non-psychotropic phytocannabinoids that have many beneficial biological properties. ...Thereafter the antiviral, antiproliferative and antibacterial properties of the derivatives and their effects on cer …
(-)-Cannabidiol (CBD) and (-)-cannabigerol (CBG) are two major non-psychotropic phytocannabinoids that have many beneficial bi …
Therapeutic Potential of Cannabis: A Comprehensive Review of Current and Future Applications.
Leinen ZJ, Mohan R, Premadasa LS, Acharya A, Mohan M, Byrareddy SN. Leinen ZJ, et al. Biomedicines. 2023 Sep 25;11(10):2630. doi: 10.3390/biomedicines11102630. Biomedicines. 2023. PMID: 37893004 Free PMC article. Review.
By researching current research and clinical studies, we probe into how cannabinoids like delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD) help to manage conditions ranging from chronic pain, persistent inflammation, cancer, inflammatory bowel disease, and ne …
By researching current research and clinical studies, we probe into how cannabinoids like delta9-tetrahydrocannabinol (THC) and cannabidi …
The Potential of Cannabidiol for Acute Respiratory Distress Syndrome in COVID-19.
Azimi S, Saghafi F, Mohammadi MH, Moghimi MH, Akhavan SA, Khataminia M, Shirvani M, Sohrevardi SM, Jamialahmadi T, Sahebnasagh A, Sahebkar A. Azimi S, et al. Curr Pharm Des. 2023;29(29):2291-2296. doi: 10.2174/0113816128275803230920094909. Curr Pharm Des. 2023. PMID: 37818584 Review.
The cytokine storm, or an excess of cytokines released locally, is assumed to be the primary cause of ARDS and mortality in COVID-19 patients. To enhance the survival rate of COVID-19 patients, early management of the cytokine storm with immunomodulato …
The cytokine storm, or an excess of cytokines released locally, is assumed to be the primary cause of ARDS and mortality in COVID- …
Subjective, behavioral and neurobiological effects of cannabis and cannabinoids in social anxiety.
Rosário BDA, Lemes JA, de Lima MP, Ribeiro DA, Viana MB. Rosário BDA, et al. Rev Neurosci. 2023 Oct 11;35(2):197-211. doi: 10.1515/revneuro-2023-0078. Print 2024 Feb 26. Rev Neurosci. 2023. PMID: 37812748 Review.
Evidence suggests that the levels of SAD are rising, in particularly after the COVID-19 pandemic. Serotonin and noradrenaline reuptake inhibitors and cognitive-behavioral therapy are effective treatments for SAD. ...The studies investigated the effects of the cannab …
Evidence suggests that the levels of SAD are rising, in particularly after the COVID-19 pandemic. Serotonin and noradrenaline …
Synthesis of cannabidiol-based compounds as ACE2 inhibitors with potential application in the treatment of COVID-19.
Marques GVL, Marques DPA, Clarindo FA, Avendaño-Villarreal JA, Guerra FS, Fernandes PD, Dos Santos EN, Gusevskaya EV, Kohlhoff M, Moreira FA, Andrade LAF, Fonseca FGD, Dos-Reis JGAC, Oliveira RB. Marques GVL, et al. Eur J Med Chem. 2023 Nov 15;260:115760. doi: 10.1016/j.ejmech.2023.115760. Epub 2023 Aug 28. Eur J Med Chem. 2023. PMID: 37657273
Used as fiber, medicine, drug, for religious, therapeutic, and hedonistic purposes along the millenia, it is mostly known for its psychoactive properties. One of its major constituents, cannabidiol (CBD), a non-psychoactive substance, among many other biological act …
Used as fiber, medicine, drug, for religious, therapeutic, and hedonistic purposes along the millenia, it is mostly known for its psychoacti …
Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial.
Hansen JS, Gustavsen S, Roshanisefat H, Kant M, Biering-Sørensen F, Andersen C, Olsson A, Chow HH, Asgari N, Hansen JR, Nielsen HH, Hansen RM, Petersen T, Oturai AB, Sellebjerg F, Sædder EA, Kasch H, Rasmussen PV, Finnerup NB, Svendsen KB. Hansen JS, et al. Pharmaceuticals (Basel). 2023 Jul 28;16(8):1079. doi: 10.3390/ph16081079. Pharmaceuticals (Basel). 2023. PMID: 37630995 Free PMC article.
Patients aged 18 years with NP (intensity >3, 9 on a numerical rating scale (NRS0-10) and/or spasticity (>3 on NRS0-10) were randomized to treatment consisting of either delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), a combination of THC&CBD …
Patients aged 18 years with NP (intensity >3, 9 on a numerical rating scale (NRS0-10) and/or spasticity (>3 on NRS0-10) were randomize …
69 results